Summary
Global Markets Direct’s, ‘Bone Marrow Transplantation - Pipeline Review, H1 2016’, provides an overview of the Bone Marrow Transplantation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplantation and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation
- The report reviews pipeline therapeutics for Bone Marrow Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Marrow Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplantation
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Anchor Therapeutics, Inc.
Boryung Pharmaceutical Co., Ltd.
Cleveland BioLabs, Inc.
Compugen Ltd.
Mesoblast Limited
Pluristem Therapeutics Inc.
Taiga Biotechnologies, Inc.
Targazyme, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bone Marrow Transplantation Overview 8
Therapeutics Development 9
Pipeline Products for Bone Marrow Transplantation - Overview 9
Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 10
Bone Marrow Transplantation - Therapeutics under Development by Companies 11
Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 12
Bone Marrow Transplantation - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Bone Marrow Transplantation - Products under Development by Companies 16
Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 17
Bone Marrow Transplantation - Companies Involved in Therapeutics Development 18
Anchor Therapeutics, Inc. 18
Boryung Pharmaceutical Co., Ltd. 19
Cleveland BioLabs, Inc. 20
Compugen Ltd. 21
Mesoblast Limited 22
Pluristem Therapeutics Inc. 23
Taiga Biotechnologies, Inc. 24
Targazyme, Inc. 25
Bone Marrow Transplantation - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(filgrastim + plerixafor) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ATI-2341 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BR-05001 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CBLB-612 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CGEN-15001 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MPC-CBE - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PLXR-18 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Protein for Bone Marrow Transplantation - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TZ-101 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Bone Marrow Transplantation - Recent Pipeline Updates 54
Bone Marrow Transplantation - Dormant Projects 65
Bone Marrow Transplantation - Discontinued Products 66
Bone Marrow Transplantation - Product Development Milestones 67
Featured News & Press Releases 67
Jan 12, 2016: Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant 67
Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology’s Annual Meeting 67
May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow 68
Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications 68
Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 69
Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 71
Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 71
Oct 27, 2014: Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 72
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 73
Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76
List of Tables
Number of Products under Development for Bone Marrow Transplantation, H1 2016 9
Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Bone Marrow Transplantation - Pipeline by Anchor Therapeutics, Inc., H1 2016 18
Bone Marrow Transplantation - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 19
Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H1 2016 20
Bone Marrow Transplantation - Pipeline by Compugen Ltd., H1 2016 21
Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H1 2016 22
Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H1 2016 23
Bone Marrow Transplantation - Pipeline by Taiga Biotechnologies, Inc., H1 2016 24
Bone Marrow Transplantation - Pipeline by Targazyme, Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 54
Bone Marrow Transplantation - Dormant Projects, H1 2016 65
Bone Marrow Transplantation - Discontinued Products, H1 2016 66
List of Figures
Number of Products under Development for Bone Marrow Transplantation, H1 2016 9
Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Mechanism of Actions, H1 2016 30
Number of Products by Stage and Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34
